ReviewTherapeutics and clinical risk management2014
Lobomycosis: epidemiology, clinical presentation, and management options.
Review in Therapeutics and clinical risk management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 58 citations in OpenAlex.
- Forest-river interfaces shape lobomycosis risk in the Amazon Basin.PLoS neglected tropical diseases · 2026Article
- Collagen depletion, not keloid formation, defines lobomycosis lesions: a paired skin analysis.Medical mycology case reports · 2026Article
- Abdominal defect reconstruction due to advanced lobomycosis with anterolateral thigh (alt) flap: a case report.Case reports in plastic surgery & hand surgery · 2026Article
- Minimally invasive punch cytology with maceration for diagnosing Jorge Lobo disease in the Brazilian Amazon.European journal of microbiology & immunology · 2025Article
- Jorge Lobo's Disease in Child with Tick Exposure, Brazil.Emerging infectious diseases · 2025Article
- Exploring the Diversity and Distribution of Medico-Veterinary Fungal Diseases in Africa: Harnessing a Multisectoral One Health Strategy for Cost-Effective Prevention and Preparedness.Journal of fungi (Basel, Switzerland) · 2025Review
- Dermatologic fungal neglected tropical diseases-Part I. Epidemiology and clinical features.Journal of the American Academy of Dermatology · 2025Review
- Human Lobomycosis Caused by Paracoccidioides (Lacazia) loboi, Panama, 2022.Emerging infectious diseases · 2023Article
- Fungal Density in Lobomycosis in French Guiana: A Proposal for a New Clinico-Histological and Therapeutic Classification.Journal of fungi (Basel, Switzerland) · 2023Article
- Lobomycosis in a Post-Covid 19 Patient: A Case Report and Review of Literature.Turk patoloji dergisi · 2023Review
- Lobomycosis Epidemiology and Management: The Quest for a Cure for the Most Neglected of Neglected Tropical Diseases.Journal of fungi (Basel, Switzerland) · 2022Review
- Article
- Natural-Product-Based Solutions for Tropical Infectious Diseases.Clinical microbiology reviews · 2021Review
- Subcutaneous Mycoses in Travelers.Current tropical medicine reports · 2020Article
- Epidemiologic and Clinical Progression of Lobomycosis among Kaiabi Indians, Brazil, 1965-2019.Emerging infectious diseases · 2020Article
- Lobomycosis in Soldiers, Colombia.Emerging infectious diseases · 2019Article
- Case Report: Molecular Confirmation of Lobomycosis in an Italian Traveler Acquired in the Amazon Region of Venezuela.The American journal of tropical medicine and hygiene · 2017Article
- Case of an Unusual Fleshy Swelling.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lobomycosis is a subcutaneous mycosis of chronic evolution caused by the Lacazia loboi fungus. Its distribution is almost exclusive in the Americas, and it has a particularly high prevalence in the Amazon basin. Cases of lobomycosis have been reported only in dolphins and humans. Its prevalence is higher among men who are active in the forest, such as rubber tappers, bushmen, miners, and Indian men. It is recognized that the traumatic implantation of the fungus on the skin is the route by which humans acquire this infection. The lesions affect mainly exposed areas such as the auricles and upper and lower limbs and are typically presented as keloid-like lesions. Currently, surgical removal is the therapeutic procedure of choice in initial cases. Despite the existing data and studies to date, the active immune mechanisms in this infection and its involvement in the control or development of lacaziosis have not been fully clarified. In recent years, little progress has been made in the appraisal of the epidemiologic aspects of the disease. So far, we have neither a population-based study nor any evaluation directed to the forest workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.